Limited progress in clinical trials for rare urologic cancers
Canadian Urological Association Journal · 20.08.2026 · 20 (12)
DOI: 10.5489/cuaj.9671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 20.08.2026. Verfasst von Etan Eigner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rappaport Faculty of Medicine, Technion Haifa, Israel.
Abstract (Originalsprache)
Introduction
We aimed to characterize the contemporary landscape, completion rates, and predictors of completion of clinical trials in testicular and penile cancers.
Methods
We performed a registry-based cohort analysis of ClinicalTrials.gov to identify interventional and observational trials in testicular or penile cancer initiated between January 1, 2000, and October 1, 2025. Trials withdrawn before enrollment, supportive-care or non-oncologic studies, epidemiologic investigations, and basket trials without predefined disease-specific enrollment targets were excluded. Extracted variables included trial design, enrollment targets, funding source, geographic region, and completion status. Firth’s penalized logistic regression was used to assess predictors of trial completion. Kaplan-Meier and Cox proportional hazards models evaluated time to trial completion.
Results
Eighty-three eligible trials were identified, including 34 penile and 49 testicular cancer studies. Most trials were early-phase, non-randomized, and small. Overall completion rates were low (38% for penile cancer and 41% for testicular cancer), with no significant difference by disease site. Trials conducted outside North America were significantly more likely to complete than North American studies (adjusted odds ratio 10.21; 95% confidence interval [CI] 2.11–68.27). Time-to-event analyses similarly demonstrated faster completion among non-North American trials (multivariable hazard ratio 5.02, 95% CI 1.84–13.66).
Conclusions
Clinical trials in rare urologic cancers demonstrate persistently low completion rates and substantial geographic disparities, highlighting the need for improved international collaboration and alternative trial frameworks to enhance trial feasibility and completion.
Autor:innen und Institutionen
- Rappaport Faculty of Medicine, Technion Haifa, Israel.
- The Department of Urology, Rambam Health Care Campus, Haifa, Israel.
- Department of Urology, University of Rochester Medical Center, Rochester, NY, United States.
Zitieren
APA
Eigner, E., Fazaa, N., Nsair, A., Atallah, M., Bandari, J., Amiel, G. E., Hoffman, A., & Malshy, K. (2026). Limited progress in clinical trials for rare urologic cancers. Canadian Urological Association Journal, 20(12). https://doi.org/10.5489/cuaj.9671
Vancouver
Eigner E, Fazaa N, Nsair A, Atallah M, Bandari J, Amiel GE, et al. Limited progress in clinical trials for rare urologic cancers. Canadian Urological Association Journal. 2026;20(12). doi:10.5489/cuaj.9671
BibTeX
@article{Eigner2026,
author = {Eigner, Etan and Fazaa, Nicola and Nsair, Ameer and Atallah, Melissa and Bandari, Jathin and Amiel, Gilad E and Hoffman, Azik and Malshy, Kamil},
title = {Limited progress in clinical trials for rare urologic cancers},
journal = {Canadian Urological Association Journal},
year = {2026},
volume = {20},
number = {12},
doi = {10.5489/cuaj.9671}
}
EUVIMED